Previous Close | 0.8951 |
Open | 0.8951 |
Bid | 0.8960 x 1000 |
Ask | 0.9500 x 1300 |
Day's Range | 0.8888 - 0.9600 |
52 Week Range | 0.7000 - 2.8800 |
Volume | 972,070 |
Avg. Volume | 1,395,146 |
Market Cap | 127M |
Beta (5Y Monthly) | 1.28 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.2350 |
Earnings Date | Nov 8, 2019 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 11.50 |
Williamsville, NY, Dec. 13, 2019 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco and hemp/cannabis plant research, announced today changes to the Company’s management. “Over the past few months we have made rapid and significant progress in strengthening 22nd Century Group as we execute against our two growth strategies,” commented James W. Cornell, Director & Chairman of the Board of 22nd Century Group.
Investments are anticipated to total $24 million, in a combination of cash and 22nd Century stock. “Our objective is to build a leading, profitable business in the fast-growing, emerging, legal hemp/cannabis space, and Panacea is a rapidly-growing, vertically-integrated, consumer-facing business with a very strong management team," Cliff Fleet, President and CEO of 22nd Century Group said in a statement.
Shareholder rights law firm Robbins LLP reminds investors that purchasers of 22nd Century Group, Inc. filed a class action complaint against the company for alleged violations of the Securities and Exchange Act of 1934 between February 18, 2016 and July 31, 2019.
Williamsville, NY, Dec. 03, 2019 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco and hemp/cannabis plant research, announced today the initial closing of an investment in Panacea Life Sciences, Inc. (Panacea), a rapidly-growing, vertically-integrated, consumer-facing company operating exclusively in the legal, hemp-derived, CBD product space. 22nd Century’s investments in Panacea over the next twelve to eighteen months are expected to total $24 million, in a combination of cash and 22nd Century stock in exchange for Panacea-issued debt and preferred equity.
Q3 2019 22nd Century Group Inc Earnings Call
Williamsville, NY, Nov. 21, 2019 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco and hemp/cannabis research, responded today to the FDA’s recent removal of the Tobacco Product Standard for Nicotine Level of Certain Tobacco Products from the Trump administration’s ‘unified agenda.’ The much anticipated Notice of Proposed Rulemaking (NPRM) for the reduced nicotine product standard, which was expected in October, was listed as being “Withdrawn” as of October 23, 2019, on the White House Office of Information and Regulatory Affairs website. The unified agenda was updated with the new information on Wednesday, November 20, 2019, as part of a semiannual review.
22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco and hemp/cannabis research, announced today that the Company filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 with the U.S. Securities and Exchange Commission. As previously announced, the Company will provide a business update for investors on an audio only webcast to be held on Friday, November 8, 2019, at 9:00 AM Eastern time. Clifford B. Fleet, President and Chief Executive Officer of 22nd Century Group, together with John Brodfuehrer, Chief Financial Officer, will conduct the webcast.
WILLIAMSVILLE, NY -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco, and hemp/cannabis plant research, announced today that the Company will provide a business update for investors via an audio-only webcast on Friday, November 8, 2019, at 9:00 AM Eastern time. Cliff Fleet, Chief Executive Officer of 22nd Century Group, together with John Brodfuehrer, Chief Financial Officer, will conduct the webcast. Interested parties are invited to listen to the live event on the 22nd Century website: www.xxiicentury.com/media/2019Q3BusinessUpdate.
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Vaping is a growing trend among youngsters, but Trump's recent threat to ban flavored e-cigarettes raises questions. Will traditional cigarette get back its lost glory?
These marijuana stocks are unlikely to have investors seeing green in the near term.
Despite another miserable month for marijuana stocks, these companies managed to buck the trend.
Most pot stocks performed poorly last month, but not these three highfliers.
President and CEO of 22nd Century Group Inc (30-Year Financial, Insider Trades) Clifford B Fleet (insider trades) bought 100,000 shares of XXII on 08/27/2019 at an average price of $1.9 a share. Continue reading...
As of late, it has definitely been a great time to be an investor 22nd Century Group.
If you're interested in 22nd Century Group, Inc. (NYSEMKT:XXII), then you might want to consider its beta (a measure...
Q2 2019 22nd Century Group Inc Earnings Call
XXII earnings call for the period ending June 30, 2019.
LOS ANGELES, CA / ACCESSWIRE / August 1, 2019 / LD Micro is pleased to announce that the LD Micro Index is being reconstituted (again) as of August 1, 2019. LD Micro has always held the belief that our ...
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
There aren't a huge number of U.S.-listed stocks with a tobacco focus, but these companies still combine to be a force in the global industry.